A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 412 participants.
Also called NCT06340854
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 412 participants
- Sponsor
- Registry
-
NCT06340854
-
- Other papers using this trial's data
- Simplified Switching to Once-Weekly Insulin Icodec Without an Initial One-Time Additional Dose Versus Once-Daily Insulin Glargine U100 in Basal Insulin-Treated Type 2 Diabetes (ONWARDS 10): A Randomised Controlled Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Bulgaria, Germany, India, Japan, Poland, Puerto Rico, South Africa, Spain
- Registry status
- Completed
Technical summary
Registry record NCT06340854. Randomized; no masking; primary purpose treatment. Start 2024-04-19 (actual); primary completion 2025-05-08 (actual). Results posted on 2026-07-02.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
- Condition
- Diabetes, Type 2
- Intervention (Drug)
- Insulin icodec
- Intervention (Drug)
- Insulin glargine
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct06340854- Content hash
2e0aca47f20c41f5f1fdebf3fd3b90f87cdc7522458213e634c5ab76e4217a3a